Bristol-Myers SquibbBMY

The company shared the first results from a late-stage study of its drug Zenbexus used alongside another treatment for multiple myeloma, a type of blood cancer. The trial focused on patients whose cancer had returned or stopped responding to other treatments, which is a particularly difficult stage of the disease to manage.

This is an important win for the company's growth strategy. As its older blockbuster drugs lose their patent protections, Bristol Myers Squibb needs a steady stream of new approvals in its cancer and immune portfolios to replace that lost revenue. Success in late-stage trials like this one is the final step before a drug can be submitted for government approval and brought to market.

Source: Business Wire

Piper Sandler raised its price target for the drugmaker to $82, up from $75 previously. The firm kept its overweight rating, which is a signal that they expect the stock to perform better than the broader market. This move puts the firm's target well above the average analyst target of $69. It suggests growing confidence that the company can successfully launch new drugs to replace the revenue it will lose when its older blockbusters lose their patent protection.

Source: Piper Sandler

Bristol Myers Squibb shared new data showing that Sotyktu, its drug for psoriatic arthritis, continues to work well for at least two years. Psoriatic arthritis is a chronic condition where the immune system attacks the joints, and keeping symptoms under control over a long period is a major challenge for patients.

This is an important win for the company's growth strategy. As its older blockbuster drugs lose patent protection, Bristol Myers Squibb needs newer treatments like Sotyktu to expand into more uses and win more of the market. Proving that a drug is both safe and effective over several years helps doctors feel more confident prescribing it over older, competing therapies.

Source: Business Wire

Bristol Myers Squibb announced its latest quarterly dividend, keeping its payout steady. For a company facing upcoming patent expirations on its biggest drugs, maintaining this dividend is a key signal that its current cash flow remains strong enough to support both its research and its shareholders. While the move is routine, it confirms the company's commitment to paying investors while it works to grow its newer portfolio of medicines.

Source: Business Wire

HSBC nudged its target for the stock up to $65 from $60 while keeping a neutral rating. This suggests the firm sees the business as fairly valued at its current price, with limited room for the stock to run much higher in the near term. Other analysts have a slightly higher average target of $68. For long-term owners, this move reflects a wait-and-see approach as the company works to replace revenue from older drugs with its newer portfolio.

Source: HSBC

Metrics we are tracking